ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.528,45
-0,39%
S&P 500
5.655,95
0,44%
Dow Jones
40.818,50
1,51%
Euro vs US Dollar
1,08812
-0,17%
Bitcoin
64.333,48
-0,80%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
29/04/202210h02Dow Jones NewsAstraZeneca Expects Decline in Covid-19 Medicine Sales in 2022 -- UpdateNASDAQ:AZNAstraZeneca PLC
29/04/202209h09Dow Jones NewsAstraZeneca Expects Decline in Covid-19 Medicine SalesNASDAQ:AZNAstraZeneca PLC
28/04/202213h00Business WireULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia GravisNASDAQ:AZNAstraZeneca PLC
28/04/202208h43Dow Jones NewsAstraZeneca Says Ultomiris Approved in US for Adults With Generalized Myasthenia GravisNASDAQ:AZNAstraZeneca PLC
27/04/202213h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancerNASDAQ:AZNAstraZeneca PLC
27/04/202209h04Dow Jones NewsAstraZeneca's Enhertu Drug Granted Breakthrough Therapy Designation in USNASDAQ:AZNAstraZeneca PLC
25/04/202214h00Business WireTremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with ImfinziNASDAQ:AZNAstraZeneca PLC
25/04/202212h26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
25/04/202209h03Dow Jones NewsAstraZeneca Liver Cancer Treatment Accepted for Priority Review in U.S.NASDAQ:AZNAstraZeneca PLC
19/04/202213h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
19/04/202208h55Dow Jones NewsAstraZeneca, Daiichi Sankyo Say FDA Has Accepted Enhertu for Priority ReviewNASDAQ:AZNAstraZeneca PLC
18/04/202214h03GlobeNewswire Inc.AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and JapanNASDAQ:AZNAstraZeneca PLC
08/04/202219h00PR Newswire (US)Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung CancerNASDAQ:AZNAstraZeneca PLC
07/04/202204h32Dow Jones NewsHBM Shares Jump 65% on Deal With AstraZenecaNASDAQ:AZNAstraZeneca PLC
04/04/202219h54PR Newswire (US)PGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing AwarenessNASDAQ:AZNAstraZeneca PLC
29/03/202208h45Dow Jones NewsAstraZeneca Gets Regulatory Approval for Ondexxya in JapanNASDAQ:AZNAstraZeneca PLC
28/03/202214h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
28/03/202208h54Dow Jones NewsAstraZeneca's Evusheld Covid-19 Preventative Drug Approved in EUNASDAQ:AZNAstraZeneca PLC
25/03/202219h07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
24/03/202219h44Dow Jones NewsAstraZeneca's Evusheld Recommended for EU Approval for Covid-19 PreventionNASDAQ:AZNAstraZeneca PLC
24/03/202219h13Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
24/03/202212h20Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
24/03/202208h46Dow Jones NewsAstraZeneca Calla Phase 3 Trial of Imfinzi Cancer Treatment Didn't Meet Primary EndpointNASDAQ:AZNAstraZeneca PLC
23/03/202214h39Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
23/03/202212h25Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
17/03/202208h53Dow Jones NewsAstraZeneca Agrees on Settlement With Chugai Pharmaceutical; To Pay $775 MillionNASDAQ:AZNAstraZeneca PLC
16/03/202219h31Dow Jones NewsAstraZeneca, Merck Say Lynparza Improved Overall Survival of Early Breast Cancer PatientsNASDAQ:AZNAstraZeneca PLC
16/03/202218h30Business WireLYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancerNASDAQ:AZNAstraZeneca PLC
14/03/202216h08Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
14/03/202209h05Dow Jones NewsAstraZeneca Says FDA Rejects Asthma Drug Fasenra For Treatment of Nasal ConditionNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

CCOM
SILVER
SILVER
AMEX
XLE
Energy Select Sector SPDR
FX
EURJPY
Euro vs Yen
DBI
DAX
DAX
USOTC
ADDYY
Adidas (QX)
CCOM
US500
US 500
FX
EURGBP
Euro vs Sterling
CCOM
US100
US Tech 100
TG
NOV
Novo Nordisk
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
RHM
Rheinmetall
AMEX
XLV
Health Care Select Sector
TG
CBK
Commerzbank
TG
MBG
MercedesBenz
DBI
MDAX
MDAX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten